Help
RSS
API
Feed
Maltego
Contact
Domain > www.tzieldhcp.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2024-11-07
13.226.184.86
(
ClassC
)
2025-07-19
204.246.191.54
(
ClassC
)
2025-08-02
204.246.191.119
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: CloudFrontDate: Sat, 19 Jul 2025 07:04:55 GMTContent-Type: text/htmlContent-Length: 167Connection: keep-aliveLocation: https://www.tzieldhcp.com/X-Cache: Redirect html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>CloudFront/center>/body>/html>
Port 443
HTTP/1.1 200 OKContent-Type: text/htmlContent-Length: 462662Connection: keep-aliveDate: Sat, 19 Jul 2025 07:04:56 GMTX-Content-Type-Options: nosniffSet-Cookie: AWSALB6MoZFAm60H4Bvj2VdyyfRdsMnKYa0XAUlB !DOCTYPE html>html langen>head>meta charSetUTF-8/>meta nameviewport contentwidthdevice-width, initial-scale1/>meta propertyog:title contentDiscover TZIELD® (teplizumab-mzwv) for HCPs/>meta propertyog:site_name contentTZIELD® (teplizumab-mzwv) HCP Site/>meta propertyog:description contentStay informed about TZIELD® (teplizumab-mzwv) for your patients./>meta propertyog:type contentwebsite/>meta propertyog:image contenthttps://www.tzieldhcp.com/assets/images/brand-logo.png/>meta namegoogle-site-verification contentsFvibN3b9-ZK7b770cub1CtZ_oiolbV3GDNrv4OHCIo/>title>TZIELDHCP.com | For US Healthcare Providers/title>meta namedescription contentTZIELD® (teplizumab-mzwv) is the first and only disease-modifying treatment indicated to delay the onset of Stage 3 Type 1 Diabetes for adult and pediatric patients aged 8 years and older with Stage 2 Type 1 Diabetes./>link relcanonical hrefhttps://www.tzieldhcp.com//>meta propertyog:url contenthttps://www.tzieldhcp.com//>script typeapplication/ld+json> { @context: http://schema.org, @type: Brand, name: TZIELD®, logo: https://www.tzieldhcp.com/assets/images/default-logo.svg, url: https://www.tzieldhcp.com/, alternateName: teplizumab-mzwv, description: TZIELD® (teplizumab-mzwv) is the first and only disease-modifying treatment indicated to delay the onset of Stage 3 Type 1 Diabetes for adult and pediatric patients aged 8 years and older with Stage 2 Type 1 Diabetes. }, { @context: http://schema.org, @type: Drug, activeIngredient: teplizumab-mzwv, administrationRoute: Vein, drugClass: Monoclonal antibodies, dosageForm: Intravenous (IV) infusion, availableStrength: 2mg/2mL, doseSchedule: Once a day every day for 14 days in a row for at least 30 minutes long, mechanismofAction: TZIELD® (teplizumab-mzwv) is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D., name: TZIELD&re
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]